Holen Sie sich die Stockscreener-App
127.79
3.46%
2.9013
Insmed Inc Aktie (INSM) Neueste Nachrichten
Insmed rated Strong Buy with 39% upside on robu... - Pluang
Here's How Much $100 Invested In Insmed 5 Years Ago Would Be Worth Today - Benzinga
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Insmed Stock Price Forecast. Should You Buy INSM? - StockInvest.us
Insmed to Present Data across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 - marketscreener.com
Insmed Grants Inducement Awards to 128 New Employees - Intellectia AI
128 new employees receive stock awards from Insmed - Stock Titan
INSM Looks 38.8% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Insmed presents new respiratory drug data at ER... - Pluang
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 - PR Newswire
The top 12 companies hiring in biopharma now - BioSpace
Insmed director Sharoky sells $637,650 of Insmed stock By Investing.com - Investing.com Nigeria
Insmed director Sharoky sells $637,650 of Insmed stock - Investing.com
Do You Believe in Insmed’s INSM) Long-Term Potential Despite Short-Term Challenges? - Yahoo Finance
Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business - Yahoo Finance
Insmed Incorporated (INSM): Investor Outlook on a Biotech Pioneer with 68.87% Potential Upside - DirectorsTalk Interviews
If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now? - Zacks Investment Research
Insmed will speak at two New York healthcare conferences in September - Stock Titan
Insmed to Present at September 2026 Investor Conferences - PR Newswire
Insmed director Melvin Sharoky sells $637,650 in shares - Investing.com
Mizuho raises Insmed stock price target to $195 on Japan approval - Investing.com
Insmed (INSM) Q2 2026 Earnings Call Transcript - AOL.com
Biotech Is Booming, But These 2 Stocks Missed the Memo - Sahm
Insmed Slides 4.3% as Recent Insider Sales and Post-Earnings Profit-Taking Weigh on Shares - Quiver Quantitative
Insmed Director Melvin Sharoky Reports Sale of 5,000 Shares via Padonia, LLC - Kalkine Media
Insmed Insider Sold Shares Worth $637,650, According to a Recent SEC Filing - marketscreener.com
Insmed (NASDAQ: INSM) director sells 5,000 shares via Padonia LLC - Stock Titan
How Insmed’s Sharply Narrowed Q2 2026 Net Loss At Insmed (INSM) Has Changed Its Investment Story - simplywall.st
BMO Capital Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $192 - Moomoo
Insmed (NASDAQ: INSM) holder Padonia targets $638K share sale - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Insmed CMO Martina Flammer sells $3.49m in company stock By Investing.com - Investing.com Australia
Insmed CMO Martina Flammer sells $3.49m in company stock - Investing.com
H.C. Wainwright Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $220 - Moomoo
13,000 Shares in Insmed, Inc. $INSM Purchased by S&CO Inc. - MarketBeat
Insmed, Inc. $INSM Shares Bought by Empowered Funds LLC - MarketBeat
Darwin Global updates Insmed Inc (INSM) ownership, reporting 3.0% beneficial stake - Stock Titan
Insmed(INSM.US) Officer Sells US$31.96 Million in Common Stock - moomoo.com
FY2026 Earnings Forecast for Insmed Issued By HC Wainwright - MarketBeat
Handelsbanken Fonder AB Grows Stake in Insmed, Inc. $INSM - MarketBeat
Insmed (NASDAQ:INSM) COO Sells 239,850 Shares - MarketBeat
Insmed Insider Sold Shares Worth $31,964,810, According to a Recent SEC Filing - marketscreener.com
Insmed Chief Operating Officer Sold Shares Worth Over $31M - TradingView
INSMED Inc (INSM) COO exercises 239,850 options and sells matching shares - Stock Titan
HC Wainwright Brokers Increase Earnings Estimates for Insmed - MarketBeat
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024 - kalkine.ca
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Minerva Neurosciences (NERV) and Zymeworks (ZYME) - The Globe and Mail
INSM (INSM) insider notice covers 239,850 shares and prior sales data - Stock Titan
INSM Maintained by JP Morgan -- Price Target Lowered to $175 - GuruFocus
Insmed (NASDAQ:INSM) Price Target Cut to $175.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
INSM Reiterates by Truist Securities -- Price Target Raised to $195 - GuruFocus
$1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today - Benzinga
H.C. Wainwright reiterates Buy on Insmed stock, $220 target By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Buy on Insmed stock, $220 target - Investing.com India
0.63%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):